Eton Pharmaceutcials Inc (ETON) Stock Price, Quote & News

Company Profile

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developi...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 847 787 7361

Website: www.etonpharma.com

Address:

21925 W. Field Parkway, Suite 235, Deer Park, United States

Ophirnews Nov. 15 at 3:27 PM

$ETON Rare disease + real betaine exposure. Eton is one of the only U.S. biopharmas with an FDA-approved Betaine Anhydrous therapy for homocystinuria. Pure-play exposure to a very niche but real functional-molecule market. Not talked about enough.

0 · Reply

bryantboy99 Nov. 7 at 4:10 PM

$ETON nothing has changed here. Good dip if you're looking to start or add to your position. These guys are on track to deliver.

0 · Reply

badgermobile Nov. 7 at 2:13 PM

$ETON loved the confidence sean and team displayed on conference call. He said that next few quarters they will be delivering even better revenue as acceptance of drugs and more benefits they are seeing from customers. They have several new drugs coming and business is executing nicely. Great long term company hope they stay it alone and not get bought for awhile

1 · Reply

badgermobile Nov. 6 at 9:07 PM

$ETON Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19 th straight quarter of sequential product sales growth Q3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP fully diluted EPS of $0.04, and Adjusted EBITDA of $2.9 million ET-600 NDA accepted for review,

0 · Reply

bryantboy99 Nov. 5 at 6:24 PM

$ETON earnings tomorrow. Someone must know something. https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-report-third-quarter-2025-financial-results

0 · Reply

bryantboy99 Nov. 4 at 11:51 AM

$ETON Vanguard reporting 5% ownership of ETON now. https://fintel.io/so/us/eton/vanguard-group

0 · Reply

ChaseDeluca Oct. 30 at 10:02 PM

You wanted early? QCLS just reset with a new ticker and a game changing mission in quantum-class computing. The float is micro. The setup is rare. This is the kind of move that doesn’t wait for confirmation. $MBRX $ETON $TOP $INVO

0 · Reply

ChaseDeluca Oct. 30 at 9:16 PM

QCLS just unlocked the kind of narrative that goes parabolic Quantum class compute + crypto infrastructure = a sector the market doesn’t know how to price — yet. One spark and this float is toast. This is the real sleeper. $ZVSA $SYBX $GTII $ETON

0 · Reply

badgermobile Oct. 22 at 1:15 PM

$ETON AVDL acquired today, I think bios like ETON undervalued will have a great q4, rates dropping and profitable could hit 24-25 by q1 with a solid Q3 report and new drug approval

0 · Reply

RunsWithDogs Oct. 17 at 5:22 PM

$ETON Barring another overall market meltdown, I'm going out on a limb to say I wouldn't expect to see anything below $17.50 again. We should begin to see anticipation for Q3 earnings during the next week or two. I'm thinking we should be back above $20 very soon. Someday, some larger funds are going to notice our increasing profit potential and we won't ever see teens again. I'm very

2 · Reply

Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

Nov 6, 2025, 11:16 PM EST - 9 days ago

Eton Pharmaceuticals, Inc. (ETON) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 9 days ago

Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

Oct 23, 2025, 4:30 PM EDT - 23 days ago

Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Aug 20, 2025, 6:50 AM EDT - 3 months ago

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

Aug 8, 2025, 3:27 PM EDT - 3 months ago

Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 5:02 AM EDT - 3 months ago

Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options

Aug 7, 2025, 4:05 PM EDT - 3 months ago

Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 28, 2025, 7:00 AM EDT - 3 months ago

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 9:33 AM EDT - 4 months ago

Eton Pharma Near Term Catalysts Vanish

Jul 8, 2025, 6:50 AM EDT - 4 months ago

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

Jun 27, 2025, 6:50 AM EDT - 5 months ago

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes

Jun 6, 2025, 5:26 PM EDT - 5 months ago

Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside

May 29, 2025, 12:42 PM EDT - 6 months ago

FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue

May 28, 2025, 5:28 PM EDT - 6 months ago

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution

May 21, 2025, 2:57 AM EDT - 6 months ago

Eton Pharmaceuticals Set To Dominate Orphan Drug Niche

May 14, 2025, 4:30 PM EDT - 6 months ago

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

May 13, 2025, 10:40 PM EDT - 6 months ago

Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:01 PM EDT - 6 months ago

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

May 1, 2025, 4:30 PM EDT - 7 months ago

Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Apr 28, 2025, 6:50 AM EDT - 7 months ago

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

Apr 1, 2025, 7:00 AM EDT - 8 months ago

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

Mar 25, 2025, 2:30 AM EDT - 8 months ago

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program

Mar 18, 2025, 7:42 PM EDT - 8 months ago

Eton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call Transcript

Mar 18, 2025, 6:50 AM EDT - 8 months ago

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Mar 14, 2025, 6:50 AM EDT - 8 months ago

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600

Mar 4, 2025, 10:00 AM EST - 9 months ago

Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®

Mar 4, 2025, 6:50 AM EST - 9 months ago

Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025

Mar 3, 2025, 6:50 AM EST - 9 months ago

Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules

Feb 7, 2025, 6:50 AM EST - 10 months ago

Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600

Feb 6, 2025, 6:50 AM EST - 10 months ago

Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400

Jan 3, 2025, 6:50 AM EST - 11 months ago

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

Dec 20, 2024, 6:50 AM EST - 11 months ago

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Dec 3, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Nov 25, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

Nov 12, 2024, 8:01 PM EST - 1 year ago

Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 1 year ago

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:30 PM EST - 1 year ago

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 3, 2024, 6:30 AM EDT - 1 year ago

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

Aug 22, 2024, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 11, 2024, 8:15 AM EDT - 1 year ago

Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 5:30 PM EDT - 1 year ago

Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jul 15, 2024, 4:05 PM EDT - 1 year ago

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

May 11, 2024, 9:34 AM EDT - 1 year ago

Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

May 1, 2024, 4:05 PM EDT - 1 year ago

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Apr 29, 2024, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Mar 22, 2024, 2:20 AM EDT - 1 year ago

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

Ophirnews Nov. 15 at 3:27 PM

0 · Reply

bryantboy99 Nov. 7 at 4:10 PM

$ETON nothing has changed here. Good dip if you're looking to start or add to your position. These guys are on track to deliver.

0 · Reply

badgermobile Nov. 7 at 2:13 PM

1 · Reply

badgermobile Nov. 6 at 9:07 PM

0 · Reply

bryantboy99 Nov. 5 at 6:24 PM

$ETON earnings tomorrow. Someone must know something. https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-report-third-quarter-2025-financial-results

0 · Reply

bryantboy99 Nov. 4 at 11:51 AM

$ETON Vanguard reporting 5% ownership of ETON now. https://fintel.io/so/us/eton/vanguard-group

0 · Reply

ChaseDeluca Oct. 30 at 10:02 PM

0 · Reply

ChaseDeluca Oct. 30 at 9:16 PM

0 · Reply

badgermobile Oct. 22 at 1:15 PM

$ETON AVDL acquired today, I think bios like ETON undervalued will have a great q4, rates dropping and profitable could hit 24-25 by q1 with a solid Q3 report and new drug approval

0 · Reply

RunsWithDogs Oct. 17 at 5:22 PM

2 · Reply

Doozio Oct. 14 at 5:25 PM

$MNND is riding them huckleberries excited TTWO da $SOUN d of turnaround tuesday ready to be $ETON then again 🐒🍌🧠⏰♾️

0 · Reply

Tennis_4567 Oct. 13 at 9:20 PM

$ETON hopefully that wasn’t Sean selling again 😆

1 · Reply

bryantboy99 Oct. 6 at 3:15 PM

$ETON crazy to think there's only 5600 watchers on here.

0 · Reply

A_Train1 Oct. 1 at 7:57 PM

$ETON gave back 7% - seems like a lot

0 · Reply

RunsWithDogs Oct. 1 at 4:45 PM

$ETON Well, that 21.27 gap is filled to say the least. The market makers overachieved but it is coming back up. Let's see some green!

0 · Reply

RunsWithDogs Sep. 30 at 6:54 PM

$ETON Hope I'm wrong, but could this be wiggling down to that 21.27 gap I referenced yesterday? Disappointing, considering it made another 52 week high today just under $23.

1 · Reply

Doozio Sep. 30 at 6:29 PM

How? It’s $ETON all the $DRUG zzzzzz 🐒🍌🧠⏰♾️. Don’t od DAVE still gotta get NUTX!! 2020FIF

0 · Reply

bryantboy99 Sep. 30 at 12:13 PM

$ETON Today?

1 · Reply

Doozio Sep. 29 at 11:12 PM

$ETON MLYS to 🐒🍌🧠⏰♾️ BILIs.

0 · Reply

Doozio Sep. 29 at 5:10 PM

$ETON appears like it’s going from MLYS TTWO BILI’s during 🐒🍌🧠⏰♾️

0 · Reply

bryantboy99 Sep. 29 at 3:41 PM

$ETON LFG!!!!!!

0 · Reply

RunsWithDogs Sep. 29 at 2:32 PM

$ETON New 52 week high, which is indeed bullish! That said, it did leave a gap this morning that will probably be filled in the next several days, so don’t be surprised if it comes back down to 21.27. I think it will be a quick test and up again. Strength is phenomenal, even on low volume! Imagine if we get news or new whales investing…

0 · Reply

Market Cap	454.30M
Revenue (ttm)	39.01M
Net Income (ttm)	-3.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	62.52
Profit Margin	-9.79%
Debt to Equity Ratio	1.31

Volume	207,400
Avg Vol	305,164
Day's Range	N/A - N/A
Shares Out	26.82M
Stochastic %K	16%
Beta	1.12
Analysts	Sell
Price Target	$30.00